This study is for older patients (70 years or older) with Diffuse Large B-cell Lymphoma (DLBCL), a type of cancer. It's looking at whether an immunotherapy drug called mosunetuzumab can help patients who still have small amounts of lymphoma DNA (called circulating tumor DNA or ctDNA) in their blood after their initial treatment with Pola-R-mini-CHP. If you have detectable ctDNA and your PET/CT scan shows your cancer is in complete remission, you might receive mosunetuzumab for 6 cycles. Researchers hope this will clear the ctDNA and lead to better outcomes. The main goal is to see how many patients clear their ctDNA after mosunetuzumab treatment, measured over 18 weeks. The study plans to enroll 40 participants, but its current status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 40 participants.

What's involved

If eligible, you would receive mosunetuzumab consolidation therapy for 6 cycles, with specific dosing on Day 1, Day 8, Day 15, and subsequent cycles. You would also have blood tests to check for ctDNA.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, ctDNA clearance, is measured from the beginning to the end of mosunetuzumab treatment at 18 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.